Exor Capital LLP Recursion Pharmaceuticals, Inc. Transaction History
Exor Capital LLP
- $2.22 Billion
- Q1 2024
A detailed history of Exor Capital LLP transactions in Recursion Pharmaceuticals, Inc. stock. As of the latest transaction made, Exor Capital LLP holds 2,175,077 shares of RXRX stock, worth $16.3 Million. This represents 0.97% of its overall portfolio holdings.
Number of Shares
2,175,077
Previous 1,875,077
16.0%
Holding current value
$16.3 Million
Previous $18.5 Million
17.29%
% of portfolio
0.97%
Previous 0.95%
Shares
3 transactions
Others Institutions Holding RXRX
# of Institutions
259Shares Held
192MCall Options Held
787KPut Options Held
1.52M-
Cathie Wood Ark Investment Management LLC | St. Petersburg, Fl24.6MShares$184 Million1.75% of portfolio
-
Baillie Gifford & CO24.1MShares$181 Million0.19% of portfolio
-
Vanguard Group Inc Valley Forge, PA16MShares$120 Million0.0% of portfolio
-
Black Rock Inc. New York, NY12.3MShares$92.4 Million0.0% of portfolio
-
Kinnevik Ab (Publ) Stockholm, V710.4MShares$78 Million100.0% of portfolio
About RECURSION PHARMACEUTICALS, INC.
- Ticker RXRX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 180,480,000
- Market Cap $1.35B
- Description
- Recursion Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase IIa clinical trial to treat cerebral cav...